Corticosteroid co-treatment induces resistance to chemotherapy in surgical resections, xenografts and established cell lines of pancreatic cancer

BMC Cancer

Volumn 6, Issue , 2006, Pages

  Zhang, Chengwen ^a   Kolb, Armin ^b   Büchler, Peter ^b   Cato, Andrew C B ^c   Mattern, Jürgen ^a   Rittgen, Werner ^a   Edler, Lutz ^a   Debatin, Klaus Michael ^d   Büchler, Markus W ^b   Friess, Helmut ^b   Herr, Ingrid ^a,b,d  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

^d UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CORTICOSTEROID; DEXAMETHASONE; GEMCITABINE; ANTIINFLAMMATORY AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER STAGING; CELL PROLIFERATION; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG RESPONSE; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; PANCREAS CARCINOMA; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; MULTIMODALITY CANCER THERAPY; NUDE MOUSE; PANCREAS TUMOR; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; UPREGULATION; XENOGRAFT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; CELL PROLIFERATION; COMBINED MODALITY THERAPY; DEXAMETHASONE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; MICE; MICE, NUDE; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 33645758083     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-6-61     Document Type: Article

References (33)

1. Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, Bassi C, Falconi M, Pederzoli P, Dervenis C, Fernandez-Cruz L, Lacaine F, Pap A, Spooner D, Kerr DJ, Friess H, Buchler MW: Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: A randomised controlled trial. Lancet 2001, 358(9293):1576-1585.
2. Keleg S., Buchler P, Ludwig R, Buchler MW, Friess H: Invasion and metastasis in pancreatic cancer. Mol Cancer 2003, 2(1):14.
3. Petty RD, Nicolson MC, Skaria S, Sinclair TS, Samuel LM, Koruth M: A phase II study of mitomycin C, cisplatin and protracted infusional 5-fluorouracil in advanced pancreatic carcinoma: efficacy and low toxicity. Ann Oncol 2003, 14(7):1100-1105.
4. Cheng L, Du C, Murray D, Tong X, Zhang YA, Chen BP, Hawley RG: A GFP reporter system to assess gene transfer and expression in human hematopoietic progenitor cells. Gene Ther 1997, 4(10):1013-1022.
5. Aapro MS: Present role of corticosteroids as antiemetics. In Recent results in cancer research Volume 121. Berlin, Springer Verlag; 1991:91-100.
6. The Italian Group for Antiemetic Research. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 1995, 332(1):1-5.
7. The Italian Group for Antiemetic Research. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med 2000, 342(21):1554-1559.
8. Kirkbride P, Bezjak A, Pater J, Zee B, Palmer MJ, Wong R, Cross P, Gulavita S, Blood P, Sun A, Dundas G, Ganguly PK, Lim J, Chowdhury AD, Kumar SE, Dar AR: Dexamethasone for the prophylaxis of radiation-induced emesis: A National Cancer Institute of Canada Clinical Trials Group phase III study. J Clin Oncol 2000, 18:1960-1966.
9. Haid M: Steroid antiemesis may be harmful. N Engl J Med 1981, 304:1237.
10. Rutz HP: Effects of corticosteroid use on treatment of solid tumours. Lancet 2002, 360(9349):1969-1970.
11. Iversen HG, Hjort GH: The influence of corticoid steroids on the frequency of spleen metastases in patients with breast cancer. Acta Pathol Microbiol Scand 1958, 44:205-212.
12. Sherlock P, Hartmann WH: Adrenal steroids and the pattern of metastases of breast cancer. JAMA 1962, 181:313-317.
13. Sorensen HT, Mellemkjaer L, Nielsen GL, Baron JA, Olsen JH, Karagas MR: Skin cancers and non-hodgkin lymphoma among users of systemic glucocorticoids: a population-based cohort study. J Natl Cancer Inst 2004, 96(9):709-711.
14. Herr I, Ucur E, Herzer K, Okouoyo S, Ridder R, Krammer PH, von Knebel Doeberitz M, Debatin KM: Glucocorticoid co-treatment induces apoptosis resistance toward cancer therapy in carcinomas. Cancer Res 2003, 63:3112-3120.
15. Wu W, Chaudhuri S, Brickley DR, Pang D, Karrison T, Conzen SD: Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. Cancer Res 2004, 64(5):1757-1764.
16. Gassler N, Zhang C, Schnabel PA, Dienemann H, Debatin KM, Mattern J, Herr I: Dexamethasone-induced cisplatin and gemcitabine resistance in lung carcinoma samples treated ex vivo. Brit J Cancer 2005, 92:1084-1088.
17. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccard C: A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991, 139:271-279.
18. Koziol JA, Maxwell DA, Fukushima M, Colmerauer ME, Pilch YH: A distribution-free test for tumor growth curve analyses with application to an animal tumor immunotherapy experiment. Biometrics 1981, 37:383-390.
19. Ioannidis JP, Hesketh PJ, Lau J: Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence. J Clin Oncol 2000, 18(19):3409-3422.
20. Brady ME, Sartiano GP, Rosenblum SL, Zaglama NE, Bauguess CT: The pharmacokinetics of single high doses of dexamethasone in cancer patients. Eur J Clin Pharmacol 1987, 32(6):593-596.
21. Cato AC, Mink S: BAG-I family of cochaperones in the modulation of nuclear receptor action. J Steroid Biochem Mol Biol 2001, 78(5):379-388.
22. Rutz HP, Herr I: Interference of glucocorticoids with apoptosis signaling and host-tumor interactions. Cancer Biol Ther 2004, 3(8):715-718.
23. Zhang C, Mattern J, Haferkamp A, Pfitzenmaier J, Debatin KM, Hohenfellner M, Rittgen W, Edler L, Groene E, Herr I: Corticosteroid-induced chemotherapy resistance in urological cancers. Cancer Biol Ther 2006, in press:.
24. Zhang C, Kolb A, Gassler N, Wenger T, Herzer K, Debatin KM, Buechler M, Edler L, Rittgen W, Friess H, Herr I: Dexamethasone desensitizes hepatocellular and colorectal tumours toward cytotoxic therapy. Cancer Letters 2005, in press:.
25. Zhang C, Marme A, Wenger T, Gutwein P, Edler L, Rittgen W, Debatin KM, Altevogt P, Herr I: Glucocorticoid-mediated inhibition of chemotherapy in ovarian carcinomas. Int J Oncol 2006, 28(2):551-8.
26. Muenstedt K, Borces D, Bohlmann MK, Zygmunt M, von Georgi R: Glucocorticoid administration in antiemetic therapy. Cancer 2004, 101:1696-1702.
27. Rutz HP, Herr I: Glucocorticoid administration in antiemetic therapy: is it safe? Cancer 2005, 103:2696.
28. Kofler R: The molecular basis of glucocorticoid-induced apoptosis of lymphoblastic leukemia cells. Histochem Cell Biol 2000, 114(1):1-7.
29. Planey SL, Litwack G: Glucocorticoid-induced apoptosis in lymphocytes. Biochem Biophys Res Commun 2000, 279(2):307-312.
30. Distelhorst CW: Recent insights into the mechanism of glucocorticosteroid-induced apoptosis. Cell Death Differ 2002, 9(1):6-19.
31. Liao Q, Guo J, Kleeff J, Zimmermann A, Buchler MW, Korc M, Friess H: Down-regulation of the dual-specificity phosphatase MKPI suppresses tumorigenicity of pancreatic cancer cells. Gastroenterology 2003, 124(7):1830-1845.
32. Shi X, Liu S, Kleeff J, Friess H, Buchler MW: Acquired resistance of pancreatic cancer cells towards 5-Fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. Oncology 2002, 62(4):354-362.
33. Shang Y, Brown M: Molecular determinants for the tissue specificity of SERMs. Science 2002, 295(5564):2465-2468.